The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10750 malaria professionals are enjoying the free benefits of MalariaWorld today

Covid-19

Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19

September 15, 2020 - 14:37 -- Open Access
Author(s): 
Kang Y, Wang H, Chen H, Wang B, Yang Y, Zhao X, Ran Q, Wei J
Reference: 
Int Heart J. 2020 Sep 12

An 84-year-old woman with hypertension, Alzheimer's disease, and chronic kidney disease presented with fever and was diagnosed with corona virus disease 2019 (COVID-19).

Malaria and COVID-19: Common and Different Findings

September 10, 2020 - 08:37 -- Open Access
Author(s): 
Di Gennaro F, Marotta C, Locantore P, Pizzol D, Putoto G
Reference: 
Trop Med Infect Dis. 2020 Sep 6;5(3):E141

Malaria and COVID-19 may have similar aspects and seem to have a strong potential for mutual influence. They have already caused millions of deaths, and the regions where malaria is endemic are at risk of further suffering from the consequences of COVID-19 due to mutual side effects, such as less access to treatment for patients with malaria due to the fear of access to healthcare centers leading to diagnostic delays and worse outcomes.

NOT Open Access | Pandemic's fallout on malaria control appears limited so far

August 24, 2020 - 15:06 -- NOT Open Access
Author(s): 
Roberts L
Reference: 
Science. 2020 Aug 21;369(6506):892

Back in March when COVID-19 hit, some scientists worried malaria cases and deaths might soar. African countries went on lockdown; worried about mass gatherings, they suspended campaigns to distribute mosquito-fighting bed nets. Fears abounded that with clinics overwhelmed by COVID-19, patients would be unable to get treatment for malaria.

Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis

August 24, 2020 - 13:13 -- Open Access
Author(s): 
Kumar N, Awasthi A, Kumari A, Sood D, Jain P, Singh T, Sharma N, Grover A, Chandra R
Reference: 
J Biomol Struct Dyn. 2020 Aug 20:1-16

Coronavirus pandemic has caused a vast number of deaths worldwide. Thus creating an urgent need to develop effective counteragents against novel coronavirus disease (COVID-19). Many antiviral drugs have been repurposed for treatment but implicated minimal recovery, which further advanced the need for clearer insights and innovation to derive effective therapeutics. Strategically, Noscapine, an approved antitussive drug with positive effects on lung linings may show favorable outcomes synergistically with antiviral drugs in trials.

Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate

August 19, 2020 - 09:15 -- Open Access
Author(s): 
Gendrot M, Duflot I, Boxberger M, Delandre O, Jardot P, Le Bideau M, Andreani J, Fonta I, Mosnier J, Rolland C, Hutter S, La Scola B, Pradines B
Reference: 
Int J Infect Dis. 2020 Aug 14:S1201-9712(20)30661-5

At the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despite drastic containment measures, this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pandemic is ongoing with particular hotspot in Southern Europe and America. Many studies predicted a similar epidemic in Africa as that currently seen in Europe and the United States of America. However, reported data do not confirm these predictions. One of the hypotheses that could explain the later emergence and spread of COVID-19 pandemic in African countries is the use of antimalarial drugs to treat malaria, and more particularly artemisinin-based combination therapy (ACT).

The potential public health consequences of COVID-19 on malaria in Africa

August 10, 2020 - 16:04 -- Open Access
Author(s): 
Sherrard-Smith E, Hogan AB, Churcher TS, et al.
Reference: 
Nat Med. 2020 Aug 7

The burden of malaria is heavily concentrated in sub-Saharan Africa (SSA) where cases and deaths associated with COVID-19 are rising1. In response, countries are implementing societal measures aimed at curtailing transmission of SARS-CoV-22,3. Despite these measures, the COVID-19 epidemic could still result in millions of deaths as local health facilities become overwhelmed4.

Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality

August 4, 2020 - 15:06 -- Open Access
Author(s): 
Osama El-Gendy A, Saeed H, Ali AMA, Zawbaa HM, Gomaa D, Harb HS, Madney YM, Osama H, Abdelrahman MA, Abdelrahim MEA
Reference: 
Vaccine. 2020 Jul 31;38(35):5564-5568

COVID-19 is affecting different countries all over the world with great variation in infection rate and death ratio. Some reports suggested a relation between the Bacillus Calmette-Guérin (BCG) vaccine and the malaria treatment to the prevention of SARS-CoV-2 infection. Some reports related infant's lower susceptibility to the COVID-19.

Identifying and combating the impacts of COVID-19 on malaria

July 30, 2020 - 14:03 -- Open Access
Author(s): 
Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, Price RN; ACREME Investigators
Reference: 
BMC Med. 2020 Jul 30; 18(1):239

The COVID-19 pandemic has resulted in millions of infections, hundreds of thousands of deaths and major societal disruption due to lockdowns and other restrictions introduced to limit disease spread. Relatively little attention has been paid to understanding how the pandemic has affected treatment, prevention and control of malaria, which is a major cause of death and disease and predominantly affects people in less well-resourced settings.

Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials

July 29, 2020 - 10:14 -- Open Access
Author(s): 
Kapepula PM, Kabengele JK, Nachega JB, et al.
Reference: 
Am J Trop Med Hyg. 2020 Jul 23

The world is currently facing a novel COVID-19 pandemic caused by SARS-CoV-2 that, as of July 12, 2020, has caused a reported 12,322,395 cases and 556,335 deaths. To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients. The search for new or repurposed drugs for treatment of COVID-19 continues.

Pages

Subscribe to RSS - Covid-19